Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
There was no significant difference in sNfL levels at baseline between UVB‐PT and non‐UVB‐PT CIS groups (20.7 and 20.1 pg/ml, respectively; p = .494), or correlations with age, EDSS score, or serum 25(OH)D levels.
Source: Serum NfL levels. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
The reasons for missing sample collection included withdrawal from the blood collection part of the study due to anxiety (n = 4 samples missed), when participants were not able to attend appointments (n = 7 samples missed), and relocation to another state following completion of phototherapy (n = 2 samples missed).
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Changes in serum neurofilament light chain levels following narrowband ultraviolet B phototherapy in clinically isolated syndrome
Study design awaiting verification · Brain and Behavior · 2022
Original publication title
Changes in serum neurofilament light chain levels following narrowband ultraviolet B phototherapy in clinically isolated syndrome
© 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
To determine whether serum neurofilament light chain (sNfL) levels are suppressed in patients with the clinically isolated syndrome (CIS) following narrowband ultraviolet B phototherapy (UVB‐PT).
Source: ObjectiveAbstract: What methods does the paper describe?
sNfL levels were measured using a sensitive single‐molecule array assay at baseline and up to 12 months in 17 patients with CIS, 10 of whom received UVB‐PT, and were compared with healthy control (HC) and early relapsing remitting multiple sclerosis (RRMS) group. sNfL levels were correlated with magnetic resonance imaging total lesion volume (LV) determined using icobrain version 4.4.1 and with clinical outcomes.
Source: MethodsAbstract: Results
Baseline median sNfL levels were significantly higher in the CIS (20.6 pg/mL, interquartile range [IQR] 13.7 to 161.4) and RRMS groups (36.6 pg/ml [IQR] 16.2 to 212.2) than in HC (10.7 pg/ml [IQR] 4.9 to 21.5) (p = .012 and p = .0002, respectively), and were strongly correlated with T2 and T1 LV at 12 months (r = .800; p = .014 and r = .833; p = .008, respectively) in the CIS group. Analysis of changes in sNfL levels over time in the CIS group showed a significant cumulative suppressive effect of UVB‐PT in the first 3 months (UVB‐PT −10.6% vs non‐UVB‐PT +58.3%; p = .04) following which the levels in the two groups converged and continued to fall.
Source: ResultsAbstract: Conclusions
Our findings provide the basis for further studies to determine the utility of sNfL levels as a marker of neuro‐axonal damage in CIS and early MS and for assessing the efficacy of new therapeutic interventions such as UVB‐PT.
Source: ConclusionsAuthors’ abstract
Abstract
Objective
To determine whether serum neurofilament light chain (sNfL) levels are suppressed in patients with the clinically isolated syndrome (CIS) following narrowband ultraviolet B phototherapy (UVB‐PT).
Methods
sNfL levels were measured using a sensitive single‐molecule array assay at baseline and up to 12 months in 17 patients with CIS, 10 of whom received UVB‐PT, and were compared with healthy control (HC) and early relapsing remitting multiple sclerosis (RRMS) group. sNfL levels were correlated with magnetic resonance imaging total lesion volume (LV) determined using icobrain version 4.4.1 and with clinical outcomes.
Results
Baseline median sNfL levels were significantly higher in the CIS (20.6 pg/mL, interquartile range [IQR] 13.7 to 161.4) and RRMS groups (36.6 pg/ml [IQR] 16.2 to 212.2) than in HC (10.7 pg/ml [IQR] 4.9 to 21.5) (p = .012 and p = .0002, respectively), and were strongly correlated with T2 and T1 LV at 12 months (r = .800; p = .014 and r = .833; p = .008, respectively) in the CIS group. Analysis of changes in sNfL levels over time in the CIS group showed a significant cumulative suppressive effect of UVB‐PT in the first 3 months (UVB‐PT −10.6% vs non‐UVB‐PT +58.3%; p = .04) following which the levels in the two groups converged and continued to fall.
Conclusions
Our findings provide the basis for further studies to determine the utility of sNfL levels as a marker of neuro‐axonal damage in CIS and early MS and for assessing the efficacy of new therapeutic interventions such as UVB‐PT.
Serum neurofilament light chain (sNfL) levels were measured using a sensitive single‐molecule array assay at baseline and up to 12 months in 17 patients with the clinically isolated syndrome (CIS), 10 of whom received UVB‐phototherapy and seven did not receive UVB‐phototherapy. Longitudinal comparisons of sNfL levels in the UVB‐phototherapy treated versus non‐UVB‐phototherapy CIS participants using a mixed‐effects model showed that over the first 3 months there was a significant cumulative suppressive effect of UVB‐phototherapy.
Publication and source details
Original title: Changes in serum neurofilament light chain levels following narrowband ultraviolet B phototherapy in clinically isolated syndrome
Marzena J. Fabis‐Pedrini; Jens Kuhle; Katherine M. A. Roberts; Stephanie Trend; Anderson P. Jones; Aleksandra Maceski; William M. Carroll; Robyn M. Lucas; Frank L. Mastaglia; Prue H. Hart; Allan G. Kermode
Brain and Behavior · 2022
* CorrespondenceProfessor Allan G. Kermode, Perron Institute for Neurological and Translational Science, The University of Western Australia, 8 Verdun Street, Nedlands, WA 6009, Australia.
Email: kermode@me.com
© 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLChttps://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.Multiple Sclerosis Research Australia 10.13039/50110000092418‐0376Multiple Sclerosis Western AustraliaNational Health and Medical Research Council of AustraliaID 1067209
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T10:18:49.252831+00:00
DOI: 10.1002/brb3.2494 · PMC8865160